All In Biotech

Drug Trial Radar · NCT05011669

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia: A Multi-Center, Prospective, Open-Label Study for 6 Weeks

Last checked: Nov 20, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Aug 16, 2021

Primary completion

Apr 16, 2023

Study completion Jun 16, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia

Conditions

  • Schizophrenia

Interventions

  • LurasidoneDrug

    Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of discontinuation due to adverse eventsTime frame: during the 6 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Sixth Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.